American Century Companies Inc. Has $3.40 Million Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

American Century Companies Inc. grew its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 7.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 262,991 shares of the company’s stock after purchasing an additional 17,363 shares during the period. American Century Companies Inc.’s holdings in Takeda Pharmaceutical were worth $3,403,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bleakley Financial Group LLC raised its stake in Takeda Pharmaceutical by 19.1% during the 1st quarter. Bleakley Financial Group LLC now owns 288,535 shares of the company’s stock worth $4,008,000 after buying an additional 46,182 shares during the period. Envestnet Portfolio Solutions Inc. raised its position in shares of Takeda Pharmaceutical by 7.4% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 25,763 shares of the company’s stock worth $358,000 after purchasing an additional 1,778 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in shares of Takeda Pharmaceutical by 0.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 130,904 shares of the company’s stock worth $1,818,000 after purchasing an additional 857 shares during the period. OLD Mission Capital LLC lifted its holdings in shares of Takeda Pharmaceutical by 1,440.9% in the 4th quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company’s stock worth $14,863,000 after purchasing an additional 973,935 shares in the last quarter. Finally, Van ECK Associates Corp grew its position in Takeda Pharmaceutical by 21.1% in the 2nd quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock valued at $26,408,000 after purchasing an additional 356,069 shares during the period. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

TAK opened at $14.65 on Friday. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $16.06. The company has a market cap of $46.61 billion, a price-to-earnings ratio of 26.64, a PEG ratio of 0.27 and a beta of 0.54. The company’s fifty day moving average price is $14.40 and its two-hundred day moving average price is $13.76. The company has a current ratio of 1.26, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Wednesday, July 31st. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.37 by $0.19. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. The company had revenue of $7.75 billion during the quarter. On average, analysts expect that Takeda Pharmaceutical Company Limited will post 1.63 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.